An Open Label,Prospective,Phase II,Clinical study to Evaluate Efficacy and safety of syp.Rubyclin in the Eczema.

Aushadhi Bhavan0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•Subjects with Diabetes Mellitus Type I and uncontrolled Diabetes Mellitus Type II.Known subjects of abnormal thyroid function.Known cases of Severe/Chronic Hepatic or Renal disease.Known subject of any active malignancy.Subjects giving history of significant cardiovascular event < 12 weeks prior to randomization.Subjects ECG demonstrating any signs of uncontrolled arrhythmia / acute ischemia.Lesions of large surface area.Subjects having known chronic, contagious infectious disease, such as active tuberculosis, Hepatitis B or C, or HIV.Subjects using any other investigational drug within 3 days prior to recruitment.Known hypersensitivity to any of the ingredients used in study drug.Pregnant and Lactating femalesSubjects currently participating in any other Clinical studyAny other medical or surgical condition considered unsuitable for subject participation in the study as per Investigator judgment.Subject having H/O keliod formation following skin injury,severe dermatitis requiring systemic corticosteroids

发起方

Aushadhi Bhavan